China Biologic Starts Plasma Collection at Yishui Station

Dec 07, 2010, 07:00 ET from China Biologic Products, Inc.

TAI'AN, China, Dec. 7, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. ("Shandong Taibang") and Guiyang Dalin Biologic Technologies Co., Ltd. ("Dalin"), and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that it has received a plasma collection license from the Shandong Province Health Department for its newly built plasma collection station in Yishui county, Shandong province and will commence commercial plasma collection on December 9, 2010.

The Company received approval to build two new plasma collection stations in Yishui and Ningyang counties in May 2010. Once the two new stations are operating, the Company will own seven of the eight plasma collection stations in Shandong province, and a total of 18 plasma collection stations nationwide, with up to 660 metric tons of plasma collection capacity when the two new plasma stations are at their optimal capacity.

"We are pleased to be commencing operations at the Yishui station," said Mr. Chao Ming Zhao, Chief Executive Officer of China Biologic. "With the additional plasma supply and the advancement of our product pipeline, we expect to continue increasing our market share in China."

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical companies in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company's website http://www.chinabiologic.com for additional information.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the ability of the Company to achieve its commercial objectives, including its ability to operate its plasma stations at optimal capacity and continue increasing its market share in China; the business strategy, plans, and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov and on the Company's website at http://www.chinabiologic.com.

All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Company Contact:

Mr. Y. Tristan Kuo

Chief Financial Officer

China Biologic Products, Inc.

Tel: +86-538-6202206

Email: IR@chinabiologic.com

www.chinabiologic.com

SOURCE China Biologic Products, Inc.



RELATED LINKS

http://www.chinabiologic.com